Recent Advances in Prostate Cancer Treatment and Drug Discovery

Sex steroids in the tumor microenvironment and prostate cancer progression

(2018) Clovis Boibessot et al.   ENDOCRINE-RELATED CANCER

Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201)

(2018) Hendrik Borgmann et al.   EUROPEAN UROLOGY

Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012

(2018) Maha Hussain et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control

(2018) Clemens Kratochwil et al.   JOURNAL OF NUCLEAR MEDICINE

Treatment-induced changes in the androgen receptor axis: Liquid biopsies as diagnostic/prognostic tools for prostate cancer

(2018) S. Prekovic et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Revisiting the role of Wnt/β-catenin signaling in prostate cancer

(2018) Jeffrey A. Schneider et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

The long tail of oncogenic drivers in prostate cancer

(2018) Joshua Armenia et al.   NATURE GENETICS

Clinical implications of PTEN loss in prostate cancer

(2018) Tamara Jamaspishvili et al.   Nature Reviews Urology

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

(2018) Matthew R. Smith et al.   NEW ENGLAND JOURNAL OF MEDICINE

LSD1 activates a lethal prostate cancer gene network independently of its demethylase function

(2018) Archana Sehrawat et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Current approaches to incorporation of radium-223 in clinical practice

(2018) Chris Parker et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer

(2018) Matti Annala et al.   Cancer Discovery

Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05)

(2018) Yoon Ji Choi et al.   Cancer Research and Treatment

Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer

(2017) Christophe Massard et al.   EUROPEAN JOURNAL OF CANCER

Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis

(2017) Larysa H.M. Rydzewska et al.   EUROPEAN JOURNAL OF CANCER

Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response

(2017) Erik Bovinder Ylitalo et al.   EUROPEAN UROLOGY

Ipilimumab for the treatment of metastatic prostate cancer

(2017) Concetta Alaia et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinations

(2017) Mark C. Markowski et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Darolutamide (ODM-201) for the treatment of prostate cancer

(2017) Neal D. Shore   EXPERT OPINION ON PHARMACOTHERAPY

Toxicity profile characteristics of novel androgen-deprivation therapy agents in patients with prostate cancer: a meta-analysis

(2017) Jianhong Zhu et al.   Expert Review of Anticancer Therapy

Advances toward LSD1 inhibitors for cancer therapy

(2017) Xiaoli Fu et al.   Future Medicinal Chemistry

Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer

(2017) Geoffrey Bryant et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Immunotherapy for Prostate Cancer: Where We Are Headed

(2017) Giuseppe Schepisi et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Targeted α Therapies for the Treatment of Bone Metastases

(2017) Fable Zustovich et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Exploiting Epigenetic Alterations in Prostate Cancer

(2017) et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Current treatment strategies for advanced prostate cancer

(2017) Kazumasa Komura et al.   INTERNATIONAL JOURNAL OF UROLOGY

PTEN loss and activation of K-RAS and β-catenin cooperate to accelerate prostate tumourigenesis

(2017) Matthew T Jefferies et al.   JOURNAL OF PATHOLOGY

The importance of DNA methylation in prostate cancer development

(2017) Charles E. Massie et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis

(2017) Samra Turajlic et al.   LANCET ONCOLOGY

Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor–Chromatin Interactions

(2017) Kush Dalal et al.   MOLECULAR CANCER THERAPEUTICS

Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

(2017) Loren M. Lasko et al.   NATURE

An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED

(2017) Wei Qi et al.   Nature Chemical Biology

TMPRSS2–ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer

(2017) Ken J Kron et al.   NATURE GENETICS

Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT–mTORC1 activation

(2017) Pingzhao Zhang et al.   NATURE MEDICINE

Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors

(2017) Hana Janouskova et al.   NATURE MEDICINE

First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication

(2017) Steven Lemery et al.   NEW ENGLAND JOURNAL OF MEDICINE

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

(2017) Karim Fizazi et al.   NEW ENGLAND JOURNAL OF MEDICINE

DNA methylation and histone modifications as epigenetic regulation in prostate cancer

(2017) Maria Nowacka-Zawisza et al.   ONCOLOGY REPORTS

A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer

(2017) Grace A. Martin et al.   PHARMACOTHERAPY

A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study

(2017) Rahul Aggarwal et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Structure of the homodimeric androgen receptor ligand-binding domain

(2017) Marta Nadal et al.   Nature Communications

Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer

(2017) Miriam S. Butler et al.   Oncotarget

Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer

(2017) Dominika E. Butler et al.   Oncotarget

Functional and therapeutic significance of EZH2 in urological cancers

(2017) Xiaobing Liu et al.   Oncotarget

Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials

(2017) Raphael B. Moreira et al.   Oncotarget

Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling

(2017) Styliani Karanika et al.   Cell Reports

Treatment of Advanced Prostate Cancer—A Review of Current Therapies and Future Promise

(2017) Semini Sumanasuriya et al.   Cold Spring Harbor Perspectives in Medicine

Androgen Signaling in Prostate Cancer

(2017) Charles Dai et al.   Cold Spring Harbor Perspectives in Medicine

Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases

(2017) Nicholas J. Vogelzang   Expert Review of Clinical Pharmacology

Glucose Metabolism in the Progression of Prostate Cancer

(2017) Francesca Cutruzzolà et al.   Frontiers in Physiology

Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy

(2017) Shuang G. Zhao et al.   JAMA Oncology

Long-term complete remission with ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients

(2017) Luc Cabel et al.   Journal for ImmunoTherapy of Cancer

AR Signaling and the PI3K Pathway in Prostate Cancer

(2017) Megan Crumbaker et al.   Cancers

Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model

(2017) Giacomo Canesin et al.   PLoS One

Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome

(2016) S. You et al.   CANCER RESEARCH

Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity

(2016) Christine Pasero et al.   CANCER RESEARCH

Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer

(2016) Y. C. Yang et al.   CLINICAL CANCER RESEARCH

Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness

(2016) Vijayalakshmi Kari et al.   EMBO REPORTS

Neuroendocrine Tumors of the Prostate: Emerging Insights from Molecular Data and Updates to the 2016 World Health Organization Classification

(2016) David S. Priemer et al.   ENDOCRINE PATHOLOGY

Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence

(2016) Isabel Coutinho et al.   ENDOCRINE-RELATED CANCER

Docetaxel Activity in the Era of Life-prolonging Hormonal Therapies for Metastatic Castration-resistant Prostate Cancer

(2016) Edoardo Francini et al.   EUROPEAN UROLOGY

The Proteome of Primary Prostate Cancer

(2016) Diego Iglesias-Gato et al.   EUROPEAN UROLOGY

Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs

(2016) Kathy A. Gelato et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

The safety and efficacy of radium-223 dichloride for the treatment of advanced prostate cancer

(2016) James M. Wilson et al.   Expert Review of Anticancer Therapy

The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer

(2016) Chiara Ciccarese et al.   Expert Review of Anticancer Therapy

The molecular underpinnings of prostate cancer: impacts on management and pathology practice

(2016) Daniel Nava Rodrigues et al.   JOURNAL OF PATHOLOGY

Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075

(2016) Emily J. Faivre et al.   MOLECULAR CANCER RESEARCH

Drug discovery in advanced prostate cancer: translating biology into therapy

(2016) Timothy A. Yap et al.   NATURE REVIEWS DRUG DISCOVERY

Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer

(2016) E. S. Antonarakis et al.   ONCOLOGIST

PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer

(2016) Kanak Raina et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review

(2016) Cara M. Statz et al.   Targeted Oncology

Biomarker Discovery in Human Prostate Cancer: an Update in Metabolomics Studies

(2016) Ana Rita Lima et al.   Translational Oncology

A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors

(2016) Cristina Saura et al.   Cancer Discovery

Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors

(2016) Shu Feng et al.   Oncotarget

Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer

(2016) Marco A. De Velasco et al.   Oncotarget

Sublethal exposure to alpha radiation (223Ra dichloride) enhances various carcinomas’ sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation

(2016) Anthony S. Malamas et al.   Oncotarget

Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer

(2016) Kristine M. Wadosky et al.   Oncotarget

CYP17 inhibitors in prostate cancer: latest evidence and clinical potential

(2016) Anitha B. Alex et al.   Therapeutic Advances in Medical Oncology

Irrefutable evidence for the use of docetaxel in newly diagnosed metastatic prostate cancer: results from the STAMPEDE and CHAARTED trials

(2015) Robert J. van Soest et al.   BMC Medicine

The genomic evolution of human prostate cancer

(2015) T Mitchell et al.   BRITISH JOURNAL OF CANCER

Feedback Suppression of PI3Kα Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3Kβ

(2015) Sarit Schwartz et al.   CANCER CELL

Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy

(2015) Peter F. Mulders et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Integrative Clinical Genomics of Advanced Prostate Cancer

(2015) Dan Robinson et al.   CELL

The Molecular Taxonomy of Primary Prostate Cancer

(2015) Adam Abeshouse et al.   CELL

High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models

(2015) Rute B. Marques et al.   EUROPEAN UROLOGY

ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer

(2015) Karim Fizazi et al.   Expert Review of Anticancer Therapy

Androgen Receptor Coactivators in Regulation of Growth and Differentiation in Prostate Cancer

(2015) Zoran Culig   JOURNAL OF CELLULAR PHYSIOLOGY

A Systematic Review of Histone Lysine-Specific Demethylase 1 and Its Inhibitors

(2015) Yi-Chao Zheng et al.   MEDICINAL RESEARCH REVIEWS

Therapeutic cancer vaccine survives biotech bust

(2015) Heidi Ledford   NATURE

The evolutionary history of lethal metastatic prostate cancer

(2015) Gunes Gundem et al.   NATURE

Targeting the MLL complex in castration-resistant prostate cancer

(2015) Rohit Malik et al.   NATURE MEDICINE

The influence of subclonal resistance mutations on targeted cancer therapy

(2015) Michael W. Schmitt et al.   Nature Reviews Clinical Oncology

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

(2015) Joaquin Mateo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies

(2015) Siu Chiu Chan et al.   NUCLEIC ACIDS RESEARCH

Comparative Effectiveness of Mitoxantrone Plus Prednisone Versus Prednisone Alone in Metastatic Castrate-Resistant Prostate Cancer After Docetaxel Failure

(2015) A. K. Green et al.   ONCOLOGIST

Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer

(2015) Vincent A. DiPippo et al.   PROSTATE

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

Battling resistance mechanisms in antihormonal prostate cancer treatment: Novel agents and combinations

(2015) Daan Joost De Maeseneer et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Targeting BET bromodomains for cancer treatment

(2015) Marie Jung et al.   Epigenomics

Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer

(2015) Changping Wu et al.   Oncotarget

Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer

(2015) Jason S. Kirk et al.   Oncotarget

Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer

(2015) Sung Han Kim et al.   PLoS One

Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer.

(2015) Anastasia Wyce et al.   Oncotarget

Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies

(2015) Anu-Maarit Moilanen et al.   Scientific Reports

Identification of a Potent Antiandrogen that Targets the BF3 Site of the Androgen Receptor and Inhibits Enzalutamide-Resistant Prostate Cancer

(2014) Ravi S.N. Munuganti et al.   CHEMISTRY & BIOLOGY

Neuroendocrine differentiation in prostate cancer: Current and emerging therapy strategies

(2014) Vincenza Conteduca et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

ETS fusion genes in prostate cancer

(2014) Delila Gasi Tandefelt et al.   ENDOCRINE-RELATED CANCER

Antibody-drug conjugates targeting prostate-specific membrane antigen

(2014) William Olson   Frontiers in Bioscience-Landmark

Inhibition of PI3K  Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel

(2014) U. Hancox et al.   MOLECULAR CANCER THERAPEUTICS

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer

(2014) Irfan A. Asangani et al.   NATURE

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

(2014) Emmanuel S. Antonarakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer

(2014) Jose D. Murga et al.   PROSTATE

Tumor clone dynamics in lethal prostate cancer

(2014) S. Carreira et al.   Science Translational Medicine

Epigenetic modifications in prostate cancer

(2014) Marjolaine Ngollo et al.   Epigenomics

Control of Embryonic Stem Cell Identity by BRD4-Dependent Transcriptional Elongation of Super-Enhancer-Associated Pluripotency Genes

(2014) Raffaella Di Micco et al.   Cell Reports

Metastatic castration-resistant prostate cancer

(2013) Ovidio Fernández et al.   ANTI-CANCER DRUGS

Punctuated Evolution of Prostate Cancer Genomes

(2013) Sylvan C. Baca et al.   CELL

Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth

(2013) Shivani Garapaty-Rao et al.   CHEMISTRY & BIOLOGY

Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval Summary

(2013) P. G. Kluetz et al.   CLINICAL CANCER RESEARCH

Targeting Fibroblast Growth Factor Pathways in Prostate Cancer

(2013) P. G. Corn et al.   CLINICAL CANCER RESEARCH

The Mutational Landscape of Prostate Cancer

(2013) Christopher E. Barbieri et al.   EUROPEAN UROLOGY

Posttranslational Modification of the Androgen Receptor in Prostate Cancer

(2013) Travis Van der Steen et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Tracking the clonal origin of lethal prostate cancer

(2013) Michael C. Haffner et al.   JOURNAL OF CLINICAL INVESTIGATION

Survival Benefit With Radium-223 Dichloride in a Mouse Model of Breast Cancer Bone Metastasis

(2013) Mari I. Suominen et al.   JNCI-Journal of the National Cancer Institute

EZH2, an epigenetic driver of prostate cancer

(2013) Yeqing Angela Yang et al.   Protein & Cell

Androgen Receptor on the Move: Boarding the Microtubule Expressway to the Nucleus

(2012) M. Thadani-Mulero et al.   CANCER RESEARCH

Distinct Patterns of Dysregulated Expression of Enzymes Involved in Androgen Synthesis and Metabolism in Metastatic Prostate Cancer Tumors

(2012) N. Mitsiades et al.   CANCER RESEARCH

A Randomized, Double-Blind, Dose-Finding, Multicenter, Phase 2 Study of Radium Chloride (Ra 223) in Patients with Bone Metastases and Castration-Resistant Prostate Cancer

(2012) Christopher C. Parker et al.   EUROPEAN UROLOGY

Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity

(2012) Himisha Beltran et al.   EUROPEAN UROLOGY

Stepwise androgen receptor dimerization

(2012) M. E. van Royen et al.   JOURNAL OF CELL SCIENCE

The mutational landscape of lethal castration-resistant prostate cancer

(2012) Catherine S. Grasso et al.   NATURE

EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent

(2012) K. Xu et al.   SCIENCE

Genome-wide DNA Methylation Events in TMPRSS2–ERG Fusion-Negative Prostate Cancers Implicate an EZH2-Dependent Mechanism with miR-26a Hypermethylation

(2012) Stefan T. Börno et al.   Cancer Discovery

Cell Autonomous Role of PTEN in Regulating Castration-Resistant Prostate Cancer Growth

(2011) David J. Mulholland et al.   CANCER CELL

Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer

(2011) Brett S. Carver et al.   CANCER CELL

Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer

(2011) Gary E Gallick et al.   Future Medicinal Chemistry

Androgen receptor-mediated gene repression

(2011) Andreas Grosse et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway

(2011) J. J. Wallin et al.   MOLECULAR CANCER THERAPEUTICS

The genomic complexity of primary human prostate cancer

(2011) Michael F. Berger et al.   NATURE

Elevated Level of Wnt5a Protein in Localized Prostate Cancer Tissue Is Associated with Better Outcome

(2011) Azharuddin Sajid Syed Khaja et al.   PLoS One

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

(2008) Arkaitz Carracedo et al.   JOURNAL OF CLINICAL INVESTIGATION